论文部分内容阅读
目的:探讨奥曲肽对预防肝癌合并门静脉高压上消化道出血的临床疗效。方法:选取2008年6月-2014年6月广州市中医医院收治的100例肝癌合并门静脉高压患者作为研究对象,随机分为两组,每组50例;对照组采取奥美拉唑治疗,而观察组采取奥曲肽治疗;对比两组患者的上消化道出血及药物不良反应发生情况。结果:观察组上消化道出血率14.00%,临床总有效率为92.00%,药物不良反应发生率为12.00%;对照组上消化道出血率48.00%,临床总有效率为74.00%,药物不良反应发生率为24.00%;两组数据组间比较,差异有统计学意义(P<0.05)。结论:奥曲肽预防肝癌合并门静脉高压上消化道出血的疗效显著,治疗安全性高,可作为急预防肝癌合并门静脉高压上消化道出血的首选治疗药物。
Objective: To investigate the clinical effect of octreotide on preventing upper gastrointestinal bleeding in hepatocellular carcinoma with portal hypertension. Methods: One hundred patients with hepatocellular carcinoma with portal hypertension treated in Guangzhou TCM Hospital from June 2008 to June 2014 were selected and randomly divided into two groups (n = 50 in each group). The control group was treated with omeprazole The observation group took octreotide treatment; compared two groups of patients with upper gastrointestinal bleeding and adverse drug reactions. Results: The upper gastrointestinal bleeding rate was 14.00%, the total clinical effective rate was 92.00% and the adverse drug reaction rate was 12.00% in the observation group. The upper gastrointestinal bleeding rate in the control group was 48.00%, the total clinical effective rate was 74.00%. The adverse drug reaction The incidence was 24.00%. There was significant difference between the two data sets (P <0.05). Conclusion: Therapeutic efficacy of octreotide in the prevention of upper gastrointestinal bleeding in patients with hepatocellular carcinoma and portal hypertension is significant and safe in treatment. It can be used as the first choice for the prevention of upper gastrointestinal bleeding in patients with hepatocellular carcinoma and portal hypertension.